Genetic Disorders

Pharma News and Updates for Actinium, Apellis, Chiesi, IVERIC, Travere, Takeda

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Actinium Announces Phase III SIERRA Trial Results; FDA Approves Apellis’s Geographic Atrophy Drug; FDA Gives Green Light to Chiesi’s Lamzede; FDA Accepts NDA and Grants Priority Review for Avacincaptad Pegol; FDA Approves Travere’s Kidney Disorder Drug; Takeda Presents Phase 3 GRAPHITE Study Results

Actinium Announces Positive Full Data Results From the Pivotal Phase III SIERRA Trial Actinium Pharmaceuticals, Inc., a pioneer in the development of targeted radiotherapies, announced positive primary and secondary endpoint results from its pivotal Phase III SIERRA trial of Iomab-B in patients aged 55 and older with active relapsed or refractory acute myeloid leukemia (r/r AML). Iomab-B achieved a high level of statistical significance (p0.0001) in the primary endpoint of durable Complete Remission (dCR) six months after initial complete remission following BMT. Iomab-B also improved the secondary endpoint of Event-Free Survival (EFS), with a 78% reduction in the ...

Explore More...

pharma-biotech-news-updates-for-novartis-boston-scientific-boehringer-ingelheim

Boston Scientific pays $336M; Boehringer Ingelheim acquires Abexxa Biologics; Oncology, RNA biotech 858 Therapeutics inks $60M Series A; Novartis acquires Arctos Medical

pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics

FDA’s New Drug Application to ALS Drug; Approval to BeiGene’s Brukinsa; Roche, Temedica Forges Digital Companionship, Shares of Sage Therapeutics Rises

charcot-marie-tooth-disease-market-cagr-trends-growth-size-share-forecast-therapies-therapy-therapeutics-treatment-drugs

Charcot-Marie-Tooth Disease Market Size Expects Growth Owing to Increasing Prevalence, Influx of Pharma Companies and Novel Therapies

pharma-happenings-for-roche-allstripes-datavant-bluewillow-shape-therapeutics

Shape Therapeutics-Roche’s Deal; AllStripes Raises $50M; Datavant-Real Chemistry’s Partnership; BlueWillow’s Nasal Vaccine

Von Hippel-Lindau Market Space Expected to Expand at a CAGR 8.3% by 2030 Owing to Increasing Prevalence and Emerging Therapies

primary-hyperoxaluria-market-cagr-size-share-trends-growth-and-key-companies

Asher Bio raises $55M; Roche halts Huntington’s phase 3 trial; Novartis’ radioligand hits goal in phase 3; EpimAb raises $120M in Series C

Market & Competitive Assessment

Market Size & Forecast Assessment

Medical Devices

Market Research

Subscription

Competitive Intelligence

Business Consulting

Customized Solutions

Request for Proposal

Blog

Newsletter/Whitepaper

Infographics

Case Study

Events

Press Release

Analysis & Perspective

Genetic Disorders

Boston Scientific pays $336M; Boehringer Ingelheim acquires Abexxa Biologics; Oncology, RNA biotech 858 Therapeutics inks $60M Series A; Novartis acquires Arctos Medical

FDA’s New Drug Application to ALS Drug; Approval to BeiGene’s Brukinsa; Roche, Temedica Forges Digital Companionship, Shares of Sage Therapeutics Rises

Charcot-Marie-Tooth Disease Market Size Expects Growth Owing to Increasing Prevalence, Influx of Pharma Companies and Novel Therapies

Shape Therapeutics-Roche’s Deal; AllStripes Raises $50M; Datavant-Real Chemistry’s Partnership; BlueWillow’s Nasal Vaccine

Von Hippel-Lindau Market Space Expected to Expand at a CAGR 8.3% by 2030 Owing to Increasing Prevalence and Emerging Therapies

Primary Hyperoxaluria Market Size Observes Growth with a Substantial CAGR

Angelman syndrome Pipeline: Unmet needs call for a robust pipeline

TLX66 in AL Amyloidosis; Takeda’s Dengue Shot; Innovent’s Cholangiocarcinoma Clinical Trial; Another Failed NASH Drug

More Views & Analysis

Who is Going to be a Trendsetter in the Hereditary Deafness Market?

Abingworth & Alebund’s Finacial Closing; Pfizer/BioNTech COVID-19 Vaccine Expanded Use; Biogen and Capsigen Deal

Rising Awareness, Key Companies, Emerging Therapies? What is Shaping the Alagille Syndrome Market

Alpha-1 Antitrypsin Deficiency: Symptoms, Treatments and Key Companies in the Market

Asher Bio raises $55M; Roche halts Huntington’s phase 3 trial; Novartis’ radioligand hits goal in phase 3; EpimAb raises $120M in Series C

Hemophilia B Market: How Pipeline Therapies are Transforming the Treatment Hemisphere?

A Royal Disease: Hemophilia

Emerging Research Continues To Transform Erythropoietic Protoporphyria Market Outlook

Subscribe to our Updates

Daily

Weekly

Monthly